Related Experiment Videos
Thrombogenic and lipid risk factors in hypertension and coronary artery disease
1Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Insights
Essential hypertension is linked to metabolic issues like platelet dysfunction and abnormal lipid profiles, increasing atherosclerosis risk. Treatments and dietary changes can improve platelet function and manage these risks.
Area of Science:
- Cardiology
- Metabolic Syndrome
- Vascular Biology
Background:
- Hypertension is often accompanied by metabolic derangements, not merely elevated blood pressure.
- Understanding these metabolic links is crucial for elucidating hypertension's mechanisms and complications.
- Platelet dysfunction and dyslipidemia are key factors associated with atherosclerosis, a common hypertension complication.
Purpose of the Study:
- To investigate the relationship between essential hypertension, platelet dysfunction, and dyslipidemia.
- To explore the impact of antihypertensive treatments and dietary modifications on platelet function.
- To highlight the association between hypertension, atherosclerotic complications, and abnormal lipid profiles, particularly hypertriglyceridemia.
Main Methods:
- Assessed platelet aggregation in patients with essential hypertension and related atherosclerotic diseases.
- Evaluated the effects of various antihypertensive medications (ACE inhibitors, calcium channel blockers, beta-blockers) and dietary changes on platelet function.
- Reviewed the association between hypertension, atherosclerotic complications, and lipid profiles, including hypertriglyceridemia.
Main Results:
- Enhanced platelet aggregation was observed in essential hypertension and associated atherosclerotic conditions.
- Antihypertensive medications and dietary interventions demonstrated potential to modify aberrant platelet function.
- A strong link was established between hypertension, atherosclerotic complications, and abnormal lipid profiles, with hypertriglyceridemia playing a significant role.
Conclusions:
- Hypertension's association with metabolic derangements, especially platelet dysfunction and dyslipidemia, is critical for understanding atherosclerosis.
- Therapeutic interventions, including medication and diet, can positively influence platelet activity in hypertensive patients.
- The development of national guidelines for lipid disorders is essential for managing cardiovascular risks in populations with increasing caloric and fat intake, such as in Taiwan.
Abstract:
Hypertension is not solely a phenomenon of elevation of systemic blood pressure. It frequently occurs in association with a great deal of metabolic derangement's and should never be regarded as coincidental only. Furthermore, a knowledge of these metabolic derangements may provide a clue to unveil the underlying mechanisms how essential hypertension and its associated complications arise. Therefore we devoted our attention to platelet dysfunction and dyslipidemia which are closely associated with atherosclerosis-the commonest complication of hypertension. We found there exists enhanced platelet aggregation in essential hypertension and a variety of its associated atherosclerotic diseases. Such an aberration in platelet function may be modified after administration of antihypertensive medications such as angiotensin converting enzyme (ACE) inhibitors, calcium channel blockades, beta blockades and dietary manipulation. We also demonstrated the close association between hypertension and its associated atherosclerotic complications and abnormal lipids profile. Hypertriglyceridemia which was initially regarded unimportant in the pathogenesis of atherosclerosis is found to be closely related to hypertension. In an intensive review, we found that people in Taiwan has experienced a huge increase in dietary calories and total fat consumption. In order to solve this emerging problem, a national guideline for diagnosis and management of lipid disorders in Taiwan was developed and announced. Through these efforts, we hope we can reduce the cardiovascular morbidity and mortality in Taiwan and even extend our experience to other countries.